ReviewPathologie (Heidelberg, Germany)2026
[Diagnosis of classic Hodgkin lymphoma and its imitators].
Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of classic Hodgkin lymphoma is made by detecting characteristic tumor cells in an equally characteristic and even dominant accompanying infiltrate. While the morphological subtype is not relevant to the treatment decision, it is all the more important to rule out "imitators" of Hodgkin lymphoma in the differential diagnosis. These are differential diagnoses that can only be recognized when the clinical context is taken into account and often only show subtle deviations in the immune profile of the neoplastic cells or the accompanying infiltrate. In younger patients, these differential diagnoses include primary infection with Epstein-Barr virus, immunodeficiency-associated lymphoproliferative disorders, and nodular lymphocyte-predominant Hodgkin lymphoma. In addition, in cases of mediastinal manifestation, a distinction must be made between primary mediastinal B‑cell lymphoma and gray zone lymphoma. In older patients, the most important "imitators" of classic Hodgkin lymphoma are T‑cell lymphomas and immunodeficiency-associated lymphoproliferative disorders.
Indexed as
Identifiers
42008185What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.